MindWalk Holdings Corp. filed patent EP26187897.9, protecting a new computational layer built on its foundational HYFT patent, EP3881326A1.1 The filing organizes biological meaning around patterns already identified by HYFT into a form reusable across MindWalk's infrastructure, customer programs, and AI workflows. The company says it is "the computational layer built on the original foundation, not a re-filing of it."1
HYFT itself is built on roughly 660 million biological patterns — universal fingerprints encoding conserved relationships between sequence, structure, and function.2 MindWalk's core bet: representing biology accurately is the hard, durable problem in AI-driven drug discovery, not model architecture.2 Before an AI system can reason about a biological question, data scattered across files, formats, and teams has to be reconnected into one governed, queryable structure.3
MindWalk gave the first public demonstration of ReefIQ, a tool built on that data layer, showing how fragmented biological information can be queried directly.3 The move fits a broader pattern: foundation models are becoming standard infrastructure for pharma R&D, not experimental add-ons. NVIDIA's BioNeMo platform is now paired with hardware partnerships at Thermo Fisher and Lilly, while competing systems — Basecamp's EDEN, Edison's Kosmos, Owkin's OwkinZero, and Boltz Lab — are being built out in parallel across the industry.
The capital shift is showing up at the corporate level too. Novo Nordisk is posting accelerating stock gains on solid Q1 earnings while pivoting away from owning cell therapy manufacturing in-house.4 Instead, it is licensing that work out to AI-driven specialists such as Cellular Intelligence.4 That pattern — established pharma players outsourcing execution to AI-native platforms rather than building the capability themselves — suggests R&D focus is rotating toward foundation-model infrastructure rather than traditional biotech buildout.
For drug developers, the emerging stack now has recognizable layers: hardware and compute (NVIDIA), biological data representation (MindWalk's HYFT/ReefIQ), and specialized discovery platforms (BioNeMo, EDEN, Kosmos, OwkinZero, Boltz Lab) sitting on top. MindWalk's patent filing is a bet that the middle layer — how biology itself gets represented computationally — is where defensible value will concentrate.